Ayala Pharmaceuticals, Inc. Common Stock
AYLA
AYLA was delisted on the 18th of January, 2023.
7 hedge funds and large institutions have $17.9M invested in Ayala Pharmaceuticals, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$11.3M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$9.26M |
| 3 |
ZP
Zimmer Partners
New York
|
+$1.74M |
| 4 |
SCM
Sio Capital Management
New York
|
+$1.59M |
| 5 |
Millennium Management
New York
|
+$859K |
Top Sellers
AYLA Hedge Fund Activity: Q2 2020 in Review
7 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Ayala Pharmaceuticals, Inc. Common Stock (AYLA) for Q2 2020, worth a combined $17.9M.
Buyers outnumbered sellers: 7 funds opened new AYLA positions and 0 closed out — a net gain of 7 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $11.3M.
- 7 institutional investors held Ayala Pharmaceuticals, Inc. Common Stock (AYLA) as of Q2 2020, up from 0 in Q1 2020.
- Funds reported $17.9M of Ayala Pharmaceuticals, Inc. Common Stock stock for Q2 2020.
- 7 funds opened new Ayala Pharmaceuticals, Inc. Common Stock positions in Q2 2020 and 0 closed out, a net change of +7 holders.
- The largest Ayala Pharmaceuticals, Inc. Common Stock buyer in Q2 2020 was Wellington Management Group, an estimated $11.3M added.
Based on aggregated 13F filings for Q2 2020.